Less SLE Disease Activity and Corticosteriod Use with Anifrolumab, Phase 3 TULIP 1 Trial Shows
News
Adding investigational anifrolumab to standard therapy lowers disease activity, limits the need for corticosteroids, and eases skin symptoms in people with moderate to severe systemic lupus erythematosus (SLE), a ... Read more